Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

Published
12 December 2018
From
BioPharma Dive
European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine)

Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO™ and PIFELTRO™ for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg).

Published
28 November 2018
From
Merch press release
Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

However, the regimen appears much less potent for those who aren’t virally suppressed.

Published
16 November 2018
From
Poz
Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual

Published
07 November 2018
By
Gus Cairns
ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.

Published
05 November 2018
From
Poz
Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

A treatment regimen containing ibalizumab (Trogarzo), a monoclonal antibody designed to block HIV, led to substantial viral load reductions in a majority of highly treatment-experienced people with

Published
02 November 2018
By
Keith Alcorn
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults with HIV-1 when treated with SYMTUZA

Published
01 November 2018
From
Janssen press release
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Biktarvy Showed High Efficacy and High Barrier to Resistance Through 96 Weeks

Published
01 November 2018
From
Gilead press release
Long-lasting HIV injection is a step closer after second GSK study

A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

Published
31 October 2018
From
Reuters
First large HIV prevention trial using antibodies will probably not be the last

The HIV Research for Prevention conference (HIVR4P 2018) in Madrid last week was dominated by studies of one type of molecule – broadly neutralising antibodies

Published
29 October 2018
By
Gus Cairns
← First12345...107Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.